181 related articles for article (PubMed ID: 17361225)
41. Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms.
Martelli AM; Papa V; Tazzari PL; Ricci F; Evangelisti C; Chiarini F; Grimaldi C; Cappellini A; Martinelli G; Ottaviani E; Pagliaro P; Horn S; Bäsecke J; Lindner LH; Eibl H; McCubrey JA
Leukemia; 2010 Apr; 24(4):687-98. PubMed ID: 20200557
[TBL] [Abstract][Full Text] [Related]
42. Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily.
Remacle-Bonnet M; Garrouste F; Baillat G; Andre F; Marvaldi J; Pommier G
Am J Pathol; 2005 Sep; 167(3):761-73. PubMed ID: 16127155
[TBL] [Abstract][Full Text] [Related]
43. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
44. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.
Meyer GE; Chesler L; Liu D; Gable K; Maddux BA; Goldenberg DD; Youngren JF; Goldfine ID; Weiss WA; Matthay KK; Rosenthal SM
J Cell Biochem; 2007 Dec; 102(6):1529-41. PubMed ID: 17486636
[TBL] [Abstract][Full Text] [Related]
45. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
[TBL] [Abstract][Full Text] [Related]
46. Treatment of breast cancer cells by IGF1R tyrosine kinase inhibitor combined with conventional systemic drugs.
Hartog H; Van Der Graaf WT; Boezen HM; Wesseling J
Anticancer Res; 2012 Apr; 32(4):1309-18. PubMed ID: 22493363
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
Pennarun B; Kleibeuker JH; Oenema T; Stegehuis JH; de Vries EG; de Jong S
Anal Cell Pathol (Amst); 2010; 33(5):229-44. PubMed ID: 20978316
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3beta constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines.
Urbanska K; Trojanek J; Del Valle L; Eldeen MB; Hofmann F; Garcia-Echeverria C; Khalili K; Reiss K
Oncogene; 2007 Apr; 26(16):2308-17. PubMed ID: 17016438
[TBL] [Abstract][Full Text] [Related]
49. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
[TBL] [Abstract][Full Text] [Related]
50. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
[TBL] [Abstract][Full Text] [Related]
51. In vivo antitumor activity and induction of insulin-like growth factor-1-resistant apoptosis by SC-alphaalphadelta9.
Vogt A; Wang AS; Johnson CS; Fabisiak JP; Wipf P; Lazo JS
J Pharmacol Exp Ther; 2000 Feb; 292(2):530-7. PubMed ID: 10640289
[TBL] [Abstract][Full Text] [Related]
52. The insulin-like growth factor-I receptor kinase inhibitor NVP-ADW742 sensitizes medulloblastoma to the effects of chemotherapy.
Zhou H; Rao J; Lin J; Yin B; Sheng H; Lin F; Zhang N; Yang L
Oncol Rep; 2011 Jun; 25(6):1565-71. PubMed ID: 21455580
[TBL] [Abstract][Full Text] [Related]
53. Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I.
Dubé PE; Rowland KJ; Brubaker PL
Endocrinology; 2008 Jan; 149(1):291-301. PubMed ID: 17884945
[TBL] [Abstract][Full Text] [Related]
54. Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis.
Tsushima H; Morimoto S; Fujishiro M; Yoshida Y; Hayakawa K; Hirai T; Miyashita T; Ikeda K; Yamaji K; Takamori K; Takasaki Y; Sekigawa I; Tamura N
Autoimmunity; 2017 Aug; 50(5):329-335. PubMed ID: 28682648
[TBL] [Abstract][Full Text] [Related]
55. Specific targeting of insulin-like growth factor 1 receptor signaling in human estrogen dependent breast cancer cell by a novel tyrosine-based benzoxazepine derivative.
Chakravarti B; Siddiqui JA; Dwivedi SK; Deshpande S; Samanta K; Bhatta RS; Panda G; Prabhakar YS; Konwar R; Sanyal S; Chattopadhyay N
Mol Cell Endocrinol; 2011 May; 338(1-2):68-78. PubMed ID: 21457754
[TBL] [Abstract][Full Text] [Related]
56. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors.
Toretsky JA; Thakar M; Eskenazi AE; Frantz CN
Cancer Res; 1999 Nov; 59(22):5745-50. PubMed ID: 10582694
[TBL] [Abstract][Full Text] [Related]
57. The activated insulin-like growth factor I receptor induces depolarization in breast epithelial cells characterized by actin filament disassembly and tyrosine dephosphorylation of FAK, Cas, and paxillin.
Guvakova MA; Surmacz E
Exp Cell Res; 1999 Aug; 251(1):244-55. PubMed ID: 10438590
[TBL] [Abstract][Full Text] [Related]
58. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
59. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
Hamilton N; Austin D; Márquez-Garbán D; Sanchez R; Chau B; Foos K; Wu Y; Vadgama J; Pietras R
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099049
[TBL] [Abstract][Full Text] [Related]
60. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.
Garofalo C; Mancarella C; Grilli A; Manara MC; Astolfi A; Marino MT; Conte A; Sigismund S; Carè A; Belfiore A; Picci P; Scotlandi K
Mol Endocrinol; 2012 Sep; 26(9):1603-16. PubMed ID: 22798295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
